Tezspire CROSSING trial met primary endpoints

27 August 2026 Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad potential of Tezspire Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated statistically